Sector Expert: André Uddin

Mackie Research Capital

Subscribe to
Streetwise Reports

Companies Commented On

  • Intellipharmaceutics International Inc.


Recent Quotes

"The FDA has granted IPCI's Rexista fast track designation."

— André Uddin, Mackie Research Capital (7/13/16)
more >

"We've modeled in a H2/17 launch for IPCI's Rexista."

— André Uddin, Mackie Research Capital (1/14/16)
more >

"TRX's gross margins for Q2/14 were 50% and were in line."

— André Uddin, Mackie Research Capital (8/12/14)
more >

"We expect TBUFF to raise its profile now with its TSX.V listing."

— André Uddin, Mackie Research Capital (5/26/14)
more >

"TBUFF's latest market opportunity gives us greater confidence in future growth."

— André Uddin, Mackie Research Capital (5/14/14)
more >

"We are initiating coverage on TBUFF with a Speculative Buy rating."

— André Uddin, Mackie Research Capital (4/9/14)
more >



Due to permission requirements, not all quotes are shown.